Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Siga Technologies has announced that its subsidiary, Siga Pharmaceuticals, has qualified as a 'small and medium-sized enterprise' with respect to its application for approval of ST-246 in Europe.
Subscribe to our email newsletter
The European Agency for the Evaluation of Medicinal Products (EMEA) established small and medium-sized enterprise (SME) as a dedicated office in 2005 to provide special assistance to small and medium-sized enterprises. SME status entitles Siga to certain fee reductions or deferrals, including reduced fees for scientific advice and certain administrative services of the EMEA, and a deferral of the fee payable for an application for marketing authorization.
ST-246 is a smallpox antiviral and Siga’s lead product candidate. SIGA has also initiated the process for obtaining marketing authorization with ST-246 with the EMEA, which is the European equivalent of the FDA. In addition, Siga engaged the SME Office in a pre-submission meeting to discuss development of ST-246 in Europe.
Eric Rose, CEO of Siga Technologies, said: “Obtaining SME status is a significant achievement in our pursuit of European regulatory approval for ST-246. SIGA will continue to work closely with the EMEA in the coming months as it moves forward in its efforts to obtain marketing authorization in Europe for ST-246.”